Qiagen (NYSE:QGEN) Releases Q4 2025 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its fourth quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.600-0.600 for the period, compared to the consensus estimate of 0.580. The company issued revenue guidance of -. Qiagen also updated its FY 2025 guidance to 2.380-2.380 EPS.

Wall Street Analyst Weigh In

QGEN has been the topic of several analyst reports. Barclays set a $53.00 target price on Qiagen and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Cowen reiterated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Wall Street Zen upgraded Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Finally, UBS Group upped their price objective on Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $49.69.

Qiagen Stock Down 2.1%

Shares of NYSE QGEN traded down $0.91 during mid-day trading on Thursday, hitting $43.14. The company had a trading volume of 588,940 shares, compared to its average volume of 1,339,220. The company has a market capitalization of $9.59 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. The firm has a 50-day simple moving average of $46.58 and a two-hundred day simple moving average of $46.47. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. Qiagen has a one year low of $37.63 and a one year high of $51.88.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.03. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.00 million during the quarter, compared to analysts’ expectations of $525.68 million. During the same quarter in the previous year, the company posted $0.57 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. On average, equities analysts expect that Qiagen will post 2.26 EPS for the current year.

Hedge Funds Weigh In On Qiagen

Institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its stake in Qiagen by 226.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after buying an additional 1,802 shares during the last quarter. Osaic Holdings Inc. increased its stake in shares of Qiagen by 101.4% during the second quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock valued at $185,000 after buying an additional 1,951 shares during the period. Pitcairn Co. purchased a new stake in Qiagen in the second quarter worth about $208,000. Captrust Financial Advisors bought a new position in shares of Qiagen in the second quarter worth approximately $221,000. Finally, Evergreen Capital Management LLC bought a new position in Qiagen during the second quarter valued at approximately $246,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.